Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma

References

• Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12:208–222.
   PubMed Web of Science ®Google Scholar
• Ji M, Liu Y, Li Q, et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5.
   PubMed Web of Science ®Google Scholar
• Staples KJ, Wilkinson TM. Reply: the PD-1-PD-L1 axis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:644–645.
   PubMed Web of Science ®Google Scholar
• Araki K, Kidokoro Y, Hosoya K, et al. Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor. Anticancer Res. 2014;34:3153–3156.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. JCO. 2015;33:3439–3446.
   PubMed Web of Science ®Google Scholar
• Saruwatari K, Ikemura S, Sekihara K, et al. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations. Lung Cancer (Amsterdam, Netherlands). 2016;91:7–14.
   PubMed Web of Science ®Google Scholar
• Yeo MK, Choi SY, Seong IO, et al. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Hum Pathol. 2017;68:103–111.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Takada K, Okamoto T, et al. Relevance between programmed death ligand 1 and radiologic invasiveness in pathologic stage I lung adenocarcinoma. Ann Thorac Surg. 2017;103:1750–1757.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–1260.
   PubMed Web of Science ®Google Scholar
• Festino L, Botti G, Lorigan P, et al. Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs. 2016;76:925–945.
   PubMed Web of Science ®Google Scholar
• Yang CY, Lin MW, Chang YL, et al. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer (Oxford, England: 1990). 2016;57:91–103.
   PubMed Web of Science ®Google Scholar
• Cserepes M, Ostoros G, Lohinai Z, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer (Oxford, England: 1990). 2014;50:1819–1828.
   PubMed Web of Science ®Google Scholar
• Lohinai Z, Hoda MA, Fabian K, et al. Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma. J Thorac Oncol. 2015;10:738–746.
   PubMed Web of Science ®Google Scholar
• Lohinai Z, Klikovits T, Moldvay J, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 2017;7:39721.
   PubMed Web of Science ®Google Scholar
• Pinter F, Papay J, Almasi A, et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn. 2008;10:160–168.
   PubMed Web of Science ®Google Scholar
• Schwab R, Pinter F, Moldavy J, et al. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. JCO. 2005;23:7736–7738.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ardizzoni A, Barberis M, et al. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an experts panel meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res. 2017;6:373–386.
   PubMed Web of Science ®Google Scholar
• Passiglia F, Bronte G, Bazan V, et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget. 2016;7:19738–19747.
   PubMedGoogle Scholar
• Chang YL, Yang CY, Lin MW, et al. High co-expression of PD-L1 and HIF-1alpha correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer (Oxford, England: 1990). 2016;60:125–135.
   PubMed Web of Science ®Google Scholar
• Pawelczyk K, Piotrowska A, Ciesielska U, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20:824–839.
   PubMed Web of Science ®Google Scholar
• Tsukamoto M, Imai K, Ishimoto T, et al. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci. 2019;110:310–320.
   PubMed Web of Science ®Google Scholar
• Hartley G, Regan D, Guth A, et al. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-alpha. Cancer Immunol Immunother. 2017;66:523–535.
   PubMed Web of Science ®Google Scholar
• Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer. 2014;2:7.
   PubMedGoogle Scholar
• Samanta D, Park Y, Ni X, et al. Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci USA. 2018;115:E1239–E1e48.
   PubMed Web of Science ®Google Scholar
• Rojko L, Reiniger L, Teglasi V, et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. J Cancer Res Clin Oncol. 2018;144:1219–1226.
   PubMed Web of Science ®Google Scholar
• Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090.
   PubMed Web of Science ®Google Scholar
• Shin J, Chung JH, Kim SH, et al. Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat. 2018. doi: 10.4143/crt2018.537
   Web of Science ®Google Scholar
• Zhang P, Ma Y, Lv C, et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 2016;107:1563–1571.
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Uehara K, Sato Y, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep. 2017;7:11373.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–695.
   PubMed Web of Science ®Google Scholar
• Derer A, Spiljar M, Baumler M, et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol. 2016;7:610.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Mogg R, Ayers M, et al. Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. J Clin Oncol. 2017;35:1.
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Zou W, Shames D, et al. OA20.01 Tumor Mutation Burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L + NSCLC patients. J Thorac Oncol. 2017;12:S321–S3S2.
   Web of Science ®Google Scholar
• Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). JCO. 2017;35:2781–2789.
   PubMed Web of Science ®Google Scholar
• Wang X, Li M. Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunol. 2019;20:4.
   PubMed Web of Science ®Google Scholar
• Evans M, O'Sullivan B, Smith M, et al. Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we? Transl Lung Cancer Res. 2018;7:682–690.
   PubMed Web of Science ®Google Scholar
• Xu J, Guo X, Jing M, et al. Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67. Onco Targets Ther. 2018;11:2269–2275.
   PubMed Web of Science ®Google Scholar
• Jiang L, Su X, Zhang T, et al. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). Oncotarget. 2017;8:26845–26857.
   PubMedGoogle Scholar
• Ng Kee Kwong F, Laggner U, McKinney O, et al. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology. 2018;72:1024–1032.
   PubMed Web of Science ®Google Scholar
• Yang W, Lu YP, Yang YZ, et al. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res. 2017;43:1602–1612.
   PubMed Web of Science ®Google Scholar
• Yang CY, Lin MW, Chang YL, et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer (Oxford, England: 1990). 2014;50:1361–1369.
   PubMed Web of Science ®Google Scholar
• D'Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95–102.
   PubMed Web of Science ®Google Scholar
• Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–688.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014;7:567–573.
   PubMed Web of Science ®Google Scholar
• Yoneshima Y, Ijichi K, Anai S, et al. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer (Amsterdam, Netherlands). 2018;118:36–40.
   PubMed Web of Science ®Google Scholar